In last trading session, Rani Therapeutics Holdings Inc (NASDAQ:RANI) saw 0.58 million shares changing hands with its beta currently measuring 0.27. Company’s recent per share price level of $1.12 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $64.45M. That closing price of RANI’s stock is at a discount of -603.57% from its 52-week high price of $7.88 and is indicating a premium of 8.04% from its 52-week low price of $1.03. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.16 million shares which gives us an average trading volume of 850.29K if we extend that period to 3-months.
For Rani Therapeutics Holdings Inc (RANI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.24 in the current quarter.
Rani Therapeutics Holdings Inc (NASDAQ:RANI) trade information
Rani Therapeutics Holdings Inc’s shares saw a change of -18.25% in year-to-date performance and have moved -4.27% in past 5-day. Rani Therapeutics Holdings Inc (NASDAQ:RANI) showed a performance of -21.68% in past 30-days. Number of shares sold short was 2.4 million shares which calculate 14.57 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 10 to the stock, which implies a rise of 88.8% to its current value. Analysts have been projecting 9 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would drop -703.57% in reaching the projected high whereas dropping to the targeted low would mean a loss of -703.57% for stock’s current value.
Rani Therapeutics Holdings Inc (RANI) estimates and forecasts
This year revenue growth is estimated to fall -83.79% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 4.78% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 8.73% while estimates for its earnings growth in next 5 years are of 14.56%.
Rani Therapeutics Holdings Inc (NASDAQ:RANI)’s Major holders
Insiders are in possession of 27.10% of company’s total shares while institution are holding 11.02 percent of that, with stock having share float percentage of 15.12%. Investors also watch the number of corporate investors in a company very closely, which is 11.02% institutions for Rani Therapeutics Holdings Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at RANI for having 0.71 million shares of worth $2.7 million. And as of 2024-06-30, it was holding 2.7265 of the company’s outstanding shares.
The second largest institutional holder is NAN FUNG GROUP HOLDINGS LTD, which was holding about 0.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.8959 of outstanding shares, having a total worth of $1.88 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 518.7 shares of worth $0.58 million or 1.55% of the total outstanding shares. The later fund manager was in possession of 172.98 shares on Dec 31, 2024 , making its stake of worth around $0.19 million in the company or a holder of 0.52% of company’s stock.
